2000

• Established the corporation
• First in the world to publicly disclose cord blood hematopoietic stem cell information

2001

• First in the world to confirm the presence of cord blood mesenchymal stem cells and successfully differentiate them into osteoblasts
• First in Korea to provide cord blood for leukemia treatment at Tokyo University Hospital in Japan

2002

• Only cord blood bank in Korea to receive international accreditation from AsiaCord

2003

• Successfully developed technology for isolating and culturing mesenchymal stem cells from frozen cord blood
• Successfully differentiated and proliferated multipotent cells from cord blood
• Officially announced medical results for liver cirrhosis treatment

2004

• Treated various diseases using cord blood mesenchymal stem cells, including cerebellar ataxia, cerebral infarction, paraplegia, Type II diabetes, multiple sclerosis, Buerger’s disease, liver cirrhosis, osteoporosis, primary biliary cirrhosis, and hypertension

2005

• Treated a U.S. spinal cord injury patient using cord blood mesenchymal stem cells and performed the first-ever cord blood transfusion for a Korean-American anemia patient at the University of California, San Francisco
• Selected as one of the top six stem cell therapy companies worldwide by Nature Biotechnology
• Provided case studies of spinal cord injury patient treatments necessary for the enactment of the U.S. stem cell therapy and research legislation, known as the ‘Smith’ Act

2006

• First in the world to be reported to Jane Pharma Biotech as a cord blood bank that conducted clinical trials using cord blood mesenchymal stem cells
• Announced preclinical results and clinical outcomes for 36 emergency cases, including spinal cord injury

2007

• Received an authoritative interpretation from the Korea Food and Drug Administration permitting the use of cord blood mesenchymal stem cell procedures

2008

• Treated over 500 patients with incurable and intractable diseases

2009

• Successfully treated a patient with irreversible cerebral infarction
• Developed Human Cord Blood Stem Cell Conditioned Media (HSCM)

2010

• Selected as a WPM R&D project operator by the Ministry of Knowledge Economy, receiving government funding of 12.5 billion KRW

2011

• Published preclinical results for spinal cord injury treatment using cord blood mesenchymal stem cells in J Neurological Science
• Secured the world’s largest collection of 100,000 units of donated cord blood

2014

• Changed the company name to Hucord Co., Ltd.

2015

• Established Hucord Vietnam branch
• Launched cosmetics containing Human Cord Blood Stem Cell Conditioned Media (HSCM)
• Signed a joint research agreement on stem cells with Korea University Anam Hospital

2016

• Signed an MOU with the Vietnam 108 Military Central Hospital
• Delivered an invited lecture at the 60th anniversary scientific seminar of Vietnam 108 Military Central Hospital
• Delivered an invited lecture at the Japan JAAS 2016 Conference
• Signed a joint research agreement on stem cells with Daegu Catholic University Medical Center

2017

• Delivered an invited lecture at the Cord Blood World Europe 2017 conference in London, UK
• Delivered an invited lecture at the Japan JAAS 2017 Conference

2018

• Established a joint venture in Hanoi, Vietnam
• Registered the Human Cord Blood Stem Cell Conditioned Media (HSCM) as a new raw material with the ICID (International Cosmetic Ingredient Dictionary).

2019

• Exported Human Cord Blood Stem Cell Conditioned Media (HSCM) to the U.S. and Japan

2020

• Registered a patent for Human Cord Blood Stem Cell Conditioned Media (HSCM)

2021

• Divided the Cord Blood Business Unit, Stem Cell Business Unit, and Conditioned Media & Cosmetics Business Unit into subsidiaries
• Registered Hucord Lab and Hucord Bio as innovation-driven venture companies

2022

• Registered a patent for Human Cord Blood Stem Cell Conditioned Media (HSCM) in Japan
• Awarded the Consumer Satisfaction Award by Money Today
• Won the Hit Brand Award in the Bio/Stem Cell category by the JoongAng Ilbo
• Selected as an Excellent Product by the Seoul Award
• Received the Korea Management Value Award by Herald Economy

2023

• Established a distribution network in Southeast Asia
• Pursued joint ventures for cell therapy overseas
• a patent for a composition for the prevention or improvement of stretch marks

2024

• Progressing with European hygiene approval for cosmetics containing Human Cord Blood Stem Cell Conditioned Media (HSCM)
• Established a distribution network in Europe
• Hucord’s Human Cord Blood Stem Cell Conditioned Media (HSCM) was uniquely selected as a raw material by Korea Kolmar, making it the only one of its kind chosen in the domestic market.